Lupin Share Price: USFDA approval ka jhatka, par litigation costs ne profit mein laga di teekhi mirchi!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
Lupin Share Price: USFDA approval ka jhatka, par litigation costs ne profit mein laga di teekhi mirchi!
Overview

Arre yaar, Lupin ke liye ek taraf achhi khabar hai - unhe USFDA se Brivaracetam Oral Solution ke liye approval mil gaya hai, matlab US mein launch ho sakta hai jahan reference drug ka sale **$135 million** tha. Lekin dusri taraf, company ke Q3 results mein profit toh badha, par litigation aur settlement ke kharchon ne sab mood kharab kar diya, jiske karan stock mein zyada tezi nahi dikhi.

Lupin ke investors ke liye ek taraf toh achhi khabar hai! Company ko USFDA se apni Brivaracetam Oral Solution ke liye mazedaar approval mil gaya hai. Iska matlab hai ki ab Lupin is drug ko United States mein launch kar payega, aur woh bhi ek aise market mein jahan pehle is reference drug ka saal ka sale $135 million tha. Ye drug un logon ke liye hai jinhe partial-onset seizures ki problem hoti hai, aur US mein epilepsy ka market toh $243 billion tak pahuchne wala hai, CAGR 5.25% ke hisab se. Toh commercial opportunity toh mast hai!

Par bhai, ye achhi khabar aayi hai company ke Q3 FY26 results ke beech mein. Revenue toh 24.3% badhkar ₹7,167.5 crore ho gaya, aur company ka US business 54% bhaga hai jo ab global revenue ka 44% hai. Net profit bhi 37.5% badhkar ₹1,175.6 crore hua, jo pichhle saal ke comparison mein kaafi achha hai. Lekin jab results ko explore karte hain, toh pata chalta hai ki ye profit itna bada hai kyunki pichle saal expenses zyada the. Asal mein, company ne antitrust litigations ke liye ₹449.4 crore aur Astellas Pharma ke saath settlement ke liye ₹134.8 crore ka provision book kiya hai. Isliye, itni achhi growth ke bawajood, stock bas 0.17% hi badha, matlab investors thode cautious hain.

Indian pharma sector abhi average 7-9% grow kar raha hai, aur Lupin ka P/E ratio 21-25x ke aas paas hai. Yeh ratio Sun Pharma (jo 37.78x hai) se kam hai, par Cipla (jo lagbhag 23.57x hai) ke barabar aur Dr. Reddy's Laboratories (jo 19.80x hai) se zyada hai. Company ka market cap lagbhag ₹1.02 trillion hai. US generic market khud $153 billion ka estimated hai, par wahan Teva, Sandoz aur Sun Pharma jaise players se bhayanak competition hai. Analysts ka average target price ₹2,426.18 ke aas paas hai, jo current level se 9.30% upar hai.

Sabse badi chinta Lupin ke liye ye litigation costs hain. Ye jo ₹449.4 crore antitrust ke liye aur ₹134.8 crore Astellas Pharma ke settlement ke liye diye gaye hain, inhone Q3 mein profit par kaafi pressure dala hai, aur pichhle quarter (Q2 FY26) ke comparison mein profit thoda kam ho gaya. Iske alawa, pichhli baar jab Pithampur facility par September 2024 mein aur Nagpur facility par September 2025 mein USFDA ne observations nikale the, tab bhi stock mein girawat aayi thi. Upar se US market mein price erosion aur regulatory changes bhi hamesha challenge rehte hain.

Brivaracetam market mein bhi competition hai; iske branded version ne pehle kaafi sales ki thi, aur market mein levetiracetam jaise generics dominant hain. Sun Pharma bhi Brivaracetam API market mein ek bada player hai, matlab supply chain mein bhi dum hai. Toh Company ka focus US market badhane aur naye products launch karne par hai, par sab kuch depend karta hai ki woh regulatory cheezon ko kaise manage karte hain aur US mein price competition ko kaise face karte hain.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.